Study of Sensory Attenuation in Functional Movement Disorders

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWestern University, Canada

About this trial

Functional movement disorders (FMD) are conditions where people experience unusual movements or difficulties with walking, not caused by a specific brain or nerve injury but related to how the brain controls movements. Functional movement disorders are common in clinical practice and can lead to significant disability and healthcare costs.

A key feature of FMD is a problem with self-agency-the feeling that we are in control of our own movements. Many patients with FMD feel that their abnormal movements happen without their control. Sensory attenuation is closely linked to self-agency. It's the brain's way of reducing the intensity of sensations caused by our own movements. For example, you can't tickle yourself because your brain knows it's your own action. In people with FMD, this process doesn't work properly. As a result, they might feel their movements are involuntary.

Previous research shows that sensory attenuation is reduced in FMD, but the studies so far have been small. This study will investigate sensory attenuation in a larger group of FMD patients and compare it with healthy individuals. The goal is to see if reduced sensory attenuation could be used as a marker to measure the severity of FMD.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial population

movement disorder clinic

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

70 Participants
are grouped into 2 trial groups
Group A: Cases
Group B: Controls

Trial outcomes

Primary outcomes

1

Sensory attenuation measurement

The primary outcome of this study is to measure sensory attenuation in patients with functional movement disorders (FMD) using the force-matching paradigm. Sensory attenuation will be quantified by calculating the ratio of matched forces to target forces in both self and external conditions.

Time frame
Day 1

Secondary outcomes

1

Correlation between WHODAS2 and PMDS with sensory attenuation.

Correlation between The World Health Organization Disability Assessment Schedule (WHODAS2) and Psychogenic Movement Disorders scale (PMDS) scores with the amount of sensory attenuation.

Time frame
Day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: